Systemic Therapy for Atopic Dermatitis: Choosing Biologics or Janus Kinase Inhibitors for Children and Adults

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Atopic dermatitis (AD) is a widespread chronic inflammatory skin condition impacting global quality of life.
• While topical treatments suffice for many, a notable patient subset necessitates systemic therapy for effective management.
• The advent of targeted therapies marks a significant shift in treating refractory AD.

Purpose of the Study:

• To provide a practical overview of current targeted systemic therapies for atopic dermatitis.
• To assist clinicians in making informed decisions regarding treatment selection, monitoring, and dosing.
• To highlight the variability in efficacy, safety, and administration of novel AD treatments.

Main Methods:

• Review of current literature on targeted systemic therapies for atopic dermatitis.
• Comparative analysis of biologic agents and Janus kinase (JAK) inhibitors.
• Discussion of individualized treatment decision-making factors.

Main Results:

• Novel targeted therapies, including biologics and JAK inhibitors, offer new options for moderate-to-severe AD.
• These therapies differ significantly in efficacy, safety profiles, administration routes, and monitoring needs.
• Individualized patient factors and comorbidities are crucial for optimal therapy selection.

Conclusions:

• Selecting the most appropriate targeted therapy for atopic dermatitis requires careful consideration of multiple factors.
• This overview aims to guide clinicians through the complexities of modern systemic AD treatment.
• Informed clinical decision-making is essential for optimizing patient outcomes in atopic dermatitis management.